Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Accounts Payables (2016 - 2025)

Altimmune (ALT) has disclosed Accounts Payables for 16 consecutive years, with $4.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables rose 324.01% to $4.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.8 million, a 324.01% increase, with the full-year FY2024 number at $211000.0, down 89.81% from a year prior.
  • Accounts Payables was $4.8 million for Q3 2025 at Altimmune, up from $851000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $5.2 million in Q1 2023 to a low of $6083.0 in Q3 2021.
  • A 5-year average of $2.3 million and a median of $2.1 million in 2023 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: plummeted 99.3% in 2021, then soared 23227.31% in 2022.
  • Altimmune's Accounts Payables stood at $2.0 million in 2021, then skyrocketed by 136.18% to $4.8 million in 2022, then plummeted by 56.91% to $2.1 million in 2023, then plummeted by 89.81% to $211000.0 in 2024, then soared by 2176.78% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Accounts Payables are $4.8 million (Q3 2025), $851000.0 (Q2 2025), and $1.1 million (Q1 2025).